Bli medlem
Bli medlem

Du är här


Orexo: Redeye: Orexo - Towards a record year

Please note that this is a translation of the analysis report which
was published on the 11 September 2018. The Court of Appeals for the
Federal Circuit took Orexo's line entirely, ruling the invalidation
of patent `330 to be erroneous. The ruling has a positive impact on
our valuation.

Read more and download the research report:

Start following companies at Redeye to recieve the latest research
within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.